Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: A meta-analysis

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 845-848

  Wen, Xiaoyang ^a   Liu, Hui ^a   Yu, Kailong ^a   Liu, Yang ^a  

^a Xinyu People's Hospital   (China)

Author keywords

Matrix metalloproteinase 2; Meta analysis; Osteosarcoma

Indexed keywords

GELATINASE A;

ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; FOLLOW UP; HUMAN; META ANALYSIS (TOPIC); OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUBLISHING; SYSTEMATIC REVIEW;

BONE NEOPLASMS; GENE EXPRESSION; HUMANS; MATRIX METALLOPROTEINASE 2; ODDS RATIO; OSTEOSARCOMA; PROGNOSIS; PUBLICATION BIAS;

EID: 84894487980     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1116-1     Document Type: Article

References (24)

1. Osborne TS, Khanna C. A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol. 2012;146:132-42.
2. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21 Suppl 7:vii320-325.
3. Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28:247-63.
4. Grimer RJ. Surgical options for children with osteosarcoma. Lancet Oncol. 2005;6:85-92.
5. Poletajew S, Fus L, Wasiutynski A. Current concepts on pathogenesis and biology ofmetastatic osteosarcoma tumors. Ortop Traumatol Rehabil. 2011;13:537-45.
6. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52-67.
7. Morrison CJ, Butler GS, Rodriguez D, Overall CM. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol. 2009;21:645-53.
8. EgebladM,Werb Z. New functions for thematrixmetalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-74.
9. Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, Aida S. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer. 2002;35:249-55.
10. Dong W, Li H, Zhang Y, Yang H, Guo M, Li L, et al. Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. Acta Biochim Biophys Sin (Shanghai). 2011;43:840-8.
11. Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K, Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol. 2006;28:33-42.
12. Li W, Ye Z, Yang D, Tao H. The expression of vascular endothelial growth factor, matrix metalloproteinases 2,9 in osteosarcoma [article in chinese]. Zhejiang Medical Journal. 2006;28:691-4.
13. Kushlinsky NE, Solovyov YN, Babkina IV, Gershtein ES, Bulicheva IV. Matrix metalloproteinases 2, 7, 9 and tissue inhibitor of matrix metalloproteinase-1 in the sera of patients with bone tumors. Bull Exp Biol Med. 2010;149:233-5.
14. Sun C, Zang Y, Yang L, Liu H, Li S. Association of malignant osteoblastoma prognosis with midkine, survivin andMMP-2 expression [article in chinese]. Medical Recapitulate. 2010;16:3833-4.
15. Xu J, Shi X, Wu S, Zhang X, Zhou Z. Expression and clinical significance of reck andMMP-2 in osteosarcoma [article in chinese]. Chinese Clinical Oncology. 2010;15:222-5.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
17. DerSimonian R, LairdN.Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
18. Mantel N, HaenszelW. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test.BMJ. 1997;315:629-34.
20. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, et al. P53 as a prognostic marker for bladder cancer: a metaanalysis and review. Lancet Oncol. 2005;6:678-86.
21. Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol. 2008;61:634-45.
22. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135-49.
23. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol. 2010;11:184-92.
24. Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene. 2010; 29:4504-16.